Table 2.

Demographics and results of predictive marker analyses for patients with pharmacodynamic evidence of drug activity

PatientSex/ageHistologic typeSmokerHER2/pHER2EGFRAverage change in SUVmax
aM/74AdenocarcinomaYes3+/negWT−56.4
bM/75NOSYesunknownWT−56.2
cM/58SquamousNounknownunknown−44.3
dF/72AdenocarcinomaYes2+/negE21 L858R−34.4
eM/63NOSYes3+/posWT−34.2
fF/72AdenocarcinomaYes1+/negWT−31.4
  • Abbreviations: NOS, not otherwise specified; WT, wild type; neg, negative; pos, positive.